ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2628

A Prospective, Double-Blind, Randomized, Placebo-Controlled Interventional Study to Evaluate the Safety and Efficacy of Enzobiotics in Pre-Dialysis CKD Patients

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism


  • Saxena, Anita, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
  • Jacob., Chakko Korula, Baptiste hospital -, Bangalore, Karnataka, India
  • Sreenivasa, Sanjay, Saptagiri Institute of Medical science, Bangalore, Karnataka, India
  • Veerappan, Ilangovan, KG Hospital, Coimbatore, Tamil Nadu, India
  • Mahaldar, Amol Ramesh, Vision and Manipal Hospitals ., GOA, Goa, India
  • Gupta, Amit, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
  • Rajagopal, Anantha subramani, Indian Statistical Institute Delhi Centre, Coimbatore, Tamilnadu, India

Synbiotics and proteolytic enzymes supplemented in CKD prevent formation of uremic toxins (UT) generated by undigested protein.
Aim : Affect of Enzobiotics in reducing generation of P-Cresols and Indoxylsulfhate and quality of life in pre dialysis patients.


Double blind, randomized, placebo controlled multicentric clinical trial CTRI/2019/01/017070 conducted over 90 Days. Eighty CKD stages 3-5 ND subjects from 5 centers divided into two groups of 40 each: group A received 1 Enzobiotic capsule TID, Group B 1 placebo capsules TID, for three months 5 minutes before food. Blood samples taken on visits 1 and 4 to measure serum creatinine, p- cresols , indoxyl sulphate (IS), platelet count (PC) hsCRP etc.


Placebo increased p-cresol by 21% while drug reduced by 23%. Enzobiotic reduced indoxyl sulfate by 500 µg/ml (from 17200 to below 16700) with reductiion in creatinine. The potential patients above p-cresol level of 20 mg/lt between drug and placebo after 90 days were found to be 53% for placebo against 33% for drug. If testing is not available, Indoxyl sulfate and p-Cresol can be predicted by 2 equations (applied for patency)
SF36 standard questionnaire revealed improvement in quality of life of treatment group. Adversity ratio reduced significantly from 0.3362 to 0.1736 P-Value 0.000 over 90 days. Daily activity limitation, emotional problems and general health reduced adversity from 60% to 47% (5.6%) 50% to 30%, 49% to 19% respectively.


Enzobiotics improve make gut microbiome favourable, can delay dialysis in CKD patients by reducing uremic toxins, CRP, thrombocytopenia and improve cardiac performance, lipid profile, and quality of life.


  • Commercial Support